Finerman G A, Gonick H C, Smith R K, Mayfield J M
Clin Orthop Relat Res. 1976 Oct(120):115-24.
Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) was administered in a dose of 20 mg/kg/d to 21 patients with symptomatic Paget's disease. All patients were treated for 6 months and then followed for an additional 6 months. There was a striking decline in serum alkaline phosphatase and urinary hydroxy-proline excretion observed after 3 months of therapy which was not significantly improved in the succeeding 3 months. Concomitantly there was marked improvement in clinical symptoms and bone scans. Following cessation of therapy, continued biochemical and clinical evidence of remission persisted. Several patients on repeat treatment with EHDP appeared to respond promptly. Side effects were minimal except for a possibly related osteomalacia and increased incidence of pathologic fractures.
以20毫克/千克/天的剂量给21例有症状的佩吉特病患者服用乙烷-1-羟基-1,1-二膦酸盐（EHDP）。所有患者接受治疗6个月，然后再随访6个月。治疗3个月后观察到血清碱性磷酸酶和尿羟脯氨酸排泄显著下降，在随后的3个月中未得到明显改善。同时，临床症状和骨扫描有明显改善。停止治疗后，生化和临床缓解的证据持续存在。几名接受EHDP重复治疗的患者似乎迅速产生了反应。除了可能相关的骨软化症和病理性骨折发生率增加外，副作用极小。
